“…Furthermore, investigation of pembrolizumab, an MAb targeting PD-1, is planned as a phase III trial in the salvage context following promising results in a phase Ib trial ( Table 1). 20 In this phase Ib trial, responses were seen in 24% of 33 pre-treated patients, and many responses were durable.…”